Predictors of Transient Congenital Primary Hypothyroidism: Data from the German Registry for Congenital Hypothyroidism (AQUAPE "HypoDok")

Abstract Neonatal screening for congenital primary hypothyroidism (CH) may not distinguish between transient (TCH) and permanent dysfunction (PCH), causing potential overtreatment and concerns in affected families. To specify the indication for interruption of therapy we analysed the German registry "HypoDok" for infants with CH, which oversees 1,625 patients from 49 participating centres in Germany and Austria from 1997 until today. 357 Patients with a thyroid gland in loco typico were identified and retrospectively grouped according to cessation (TCH n=24) or continuation (PCH n=333) of L-Thyroxine (L-T4) treatment at 2 years of age. The receiver operating characteristic (ROC) analysis was performed to identify cut-offs predicting TCH by screening TSH concentrations and L-T4 dosages. Gestational ages, birth weights and prevalence of associated malformations were comparable in both groups. The cut-off screening TSH concentration was 73 mU/L. The cut-off daily L-T4 dosage at 1 year was 3.1 µg/kg (90% sensitivity, 63% specificity; 36 µg/d) and at 2 years of age 2.95 µg/kg (91% sensitivity, 59% specificity; 40 µg/d). At 2 years of age, specificity (71%) increased when these both parameters were considered together. Conclusion: The decision to continue or cease L-T4 treatment at 2 years of age in CH patients diagnosed in neonatal screening may be based on their screening TSH concentrations and individual L-T4 dosages at 1 and 2 years of age. Thus, TCH and PCH may be distinguished; overtreatment avoided, and affected families reassured.